Handel nachbörslich: 1.90 -0.02 -1.04%

Acurx Pharmaceuticals Inc (ACXP)

Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten

Acurx Pharmaceuticals Inc (ACXP)

Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten

Acurx reports ibezapolstat's positive microbiome effects and Anthrax activity - Investing.com

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues - StockTitan

Acurx readies ibezapolstat for Phase 3 CDI trials - Investing.com

Acurx readies ibezapolstat for Phase 3 CDI trials - Investing.com India

Acurx announces results of Phase 2 ibezapolstat trial in C. difficile Infection - TipRanks

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium - StockTitan

Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Down 7% - Defense World

ACM Research, Inc. (ACMR) Dips More Than Broader Market: What You Should Know - Yahoo Finance

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha

ACM Research Inc (ACMR) stock: A year of ups and downs - US Post News

Investing in Acrivon Therapeutics Inc (ACRV) Is Getting More Attractive - Knox Daily

Financial Metrics Exploration: Understanding Acrivon Therapeutics Inc (ACRV) Through Ratios - The Dwinnex

Market Watch: Aclarion Inc (ACON)’s Noteworthy Drop, Closing at 0.18 - The Dwinnex

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of "Buy" from Analysts - MarketBeat

Carborundum Universal shares surge over 4% following acquisition and investment plans - Business Upturn

ACM Research Inc [ACMR] Insider Activity: An Update for Investors - Knox Daily

Ratios Uncovered: Breaking Down ACM Research Inc (ACMR)’s Trailing Twelve Months Metrics - The Dwinnex

Healthy Upside Potential: ACM Research Inc (ACMR) - SETE News

Acrivon Therapeutics: Promising Trial Results and FDA Clearance - TipRanks

Acrivon Therapeutics upgraded to Buy on cancer data at Ladenburg - TipRanks

New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 10:30 PM PT September 9, 2024 09:15 ET - StreetInsider.com

New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 10:30 PM PT September 9, 2024 09:15 ET - AccessWire

New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 10:30 PM PT September 9, 2024 09:15 ET - Yahoo Canada Finance

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Down 5.4% in August - Defense World

New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, - Daily Guardian Canada

New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT - GlobeNewswire

ACXPAcurx Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

We're A Little Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Rate - Yahoo Finance

vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga

New to The Street Announces Episode 590, Five Corporate - GlobeNewswire

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update - Defense World

Zentalis Pharmaceuticals, Inc. Expected to Earn Q3 2024 Earnings of ($0.86) Per Share (NASDAQ:ZNTL) - Defense World

HC Wainwright Analysts Increase Earnings Estimates for Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) - Defense World

Q3 2024 Earnings Estimate for Akero Therapeutics, Inc. (NASDAQ:AKRO) Issued By HC Wainwright - Defense World

HC Wainwright Weighs in on Akebia Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:AKBA) - Defense World

Cymat Technologies (CVE:CYM) Trading 29.6% Higher - Defense World

Acurx Pharmaceuticals (NASDAQ:ACXP) Earns Buy Rating from HC Wainwright - Defense World

Cetera Advisors LLC Purchases Shares of 40,900 TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World

Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely - Simply Wall St

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2024 Earnings Call Transcript - Insider Monkey

Earnings call: Acurx Pharmaceuticals outlines funding strategies for Phase 3 trials - Investing.com India

Earnings call: Acurx Pharmaceuticals outlines funding strategies for Phase 3 trials - Investing.com

Acurx Pharmaceuticals Reports Second Quarter 2024 Results and Provides Business Update - citybiz

New to The Street TV Announces Episode 583, Five Riveting - GlobeNewswire

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript - Seeking Alpha

New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET - ForexTV.com

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update - StockTitan

Acurx Pharmaceuticals (ACXP) Set to Announce Earnings on Friday - American Banking and Market News

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by StockNews.com - Defense World

Acurx Pharmaceuticals (ACXP) Set to Announce Quarterly Earnings on Friday - Defense World

Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Declines By 8.6% - Defense World

ACXP’s price-to-sales ratio: Is it a good investment opportunity? - US Post News

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome - Lelezard

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome - StockTitan

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update - StockTitan

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Down 7.1% in June - Defense World

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference - StockTitan

14000 Shares in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Bought by NBC Securities Inc. - Defense World

How Do Things Look For Acurx Pharmaceuticals Inc (NASDAQ: ACXP) In The Short-Term? – Stocks Register - Stocks Register

Closing Strong: Acurx Pharmaceuticals Inc (ACXP) Ends at 2.25, Down -5.46 from Last Close – DWinneX - The Dwinnex

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Significant Growth in Short Interest - Defense World

Acurx Pharmaceuticals (NASDAQ:ACXP) Trading Up 6.3% - Defense World

New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored ... - GlobeNewswire

New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored ... - Yahoo Canada Finance

New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PT - Yahoo Finance

12 Health Care Stocks Moving In Tuesday's After-Market SessionAcurx Pharmaceuticals (NASDAQ:ACXP), Biodexa ... - Benzinga

Q2 2024 Earnings Forecast for Cabaletta Bio, Inc. Issued By HC Wainwright (NASDAQ:CABA) - Defense World

Ähnlich wie ACXP